ER1120 .pdf
File information
Original filename: ER1120.pdf
This PDF 1.7 document has been generated by Microsoft® Word 2016, and has been sent on pdf-archive.com on 10/10/2018 at 12:42, from IP address 92.253.x.x.
The current document download page has been viewed 309 times.
File size: 206 KB (4 pages).
Privacy: public file
Share on social networks
Link to this file download page
Document preview
22/02/2017
WHO Classification:
Towards Personalized Medicine in Haematology
CityWest Hotel, Saggart (Dublin), Ireland
9-11 March, 2017
Chairs: Mario Cazzola (Pavia), Matteo G Della Porta (Milan), Torsten Haferlach (Munich),
Eva Hellstrdm-Lindberg (Stockholm), Andreas Hochhaus (Jena)
Thursday, March 9,2017
13:00-13:15 Welcome
SESSION I
Introduction to the training course
Genomics of Haematological Malignancies for the Practicing Clinician
Chair: Bob Lowenberg (Rotterdam)
13:15-13:40
13:40-13:45
ABCs of genomics Nick Cross (Salisbury)
Discussion
13:45-14:10
14:10-14:15
Genomic applications in the clinic: are we ready? Andreas Hochhaus (Jena)
Discussion
14:15-14:40
14:40-14:45
Next-generation sequencing data analysis: critical issues Torsten Haferlach (Munich)
Discussion
14:45-15:15
Round table/general discussion
The 2016 WHO Classification of Haematological Malignancies: what’s new?
Chair: Mario Cazzola (Pavia)
15:15-15:40
15:40-15:45
Update of the WHO classification of myeloid malignancies Mario Cazzola (Pavia)
Discussion
15:45-16:10
16:10-16:15
Update of the WHO classification of lymphoid malignancies Steven Swcrdlow (Pittsburgh)
Discussion
16:15-16:45
Round table/general discussion
16:45-17:15
Coffee Break
1
SESSION II
Biologically-Based Acute Myeloid Leukaemia (AML) Therapy
Chair: Torsten Haferlach (Munich)
17:15-17:40
17:40-17:45
Translational implications of the medical genomics Torsten Haferlach (Munich)
in AML
Discussion
17:45-18:10
18:10-18:15
Genotype-tailored therapy of AML Hartmut Dohncr (Ulm)
Discussion
18:15-18:40
18:40-18:45
Towards personalized medicine in AML Bob Ldwcnberg (Rotterdam)
Discussion
18:45-19:10
19:10-19:15
Precision medicine in AML: hope, hype or both? Robert P. Gale (London)
Discussion
19:15-19:30
Round table/general discussion
19:30
Poster Viewing and Get together
SESSION III
Molecular Haematology: the Paradigm of Myeloproliferative Neoplasms (MPN)
Chair: Andreas Hochhaus (Jena)
08:45-09:10
09:10-09:15
The evolving genomic landscape of Philadelphia-negative Mario Cazzola (Pavia)
classical MPN
Discussion
09:15-09:40
09:40-09:45
Genotype-based clinical decision making in MPN Francesco Passamonti (Varese)
Discussion
09:45-10:10
10:10-10:15
The future of JAK inhibition in MPN Alessandro Vannucchi (Florence)
Discussion
10:15-10:45
Round table/general discussion
10:45-11:15
Coffee Break
SESSION IV
Modern Diagnostics Applied to the Evaluation of Minimal Residual Disease:
the example of CML
Chair: Nick Cross (Salisbury)
11:15-11:40
11:40-11:45
CML monitoring: why, which, where and when? Andreas Hochhaus (Jena)
Discussion
11:45-12:10
12:10-12:15
Current status of standardization efforts for PCR in CML Nick Cross (Salisbury)
Discussion
12:15-12:40
12:40-12:45
Clinical significance of NGS in second-line Simona Soverini (Bologna)
treatment and beyond
Discussion
12:45-13:15
Round table/general discussion
2
13:15-14:15
SESSION V
Lunch
Changing Paradigms in Acute Lymphocytic Leukaemia (ALL):
from the genome to the patient
Chair: Jacob Rowe (Jerusalem)
14:15-14:40
14:40-14:45
The genomic landscape of ALL Christine Harrison (Newcastle)
Discussion
14:45-15:10
15:10-15:15
Targeting signaling pathways in ALL: new insights Charles Mullighan (Memphis)
Discussion
15:15-15:40
15:40-15:45
Clinically defining and managing high-risk adult patients Jacob Rowe (Jerusalem)
with ALL
Discussion
15:45-16:15
Round table/general discussion
16:15-16:45
Coffee Break
SESSION VI
16:45-17:10
17:10-17:15
The Dawn of the Molecular Era in Myelodysplastic Syndromes (MDS) and
Myclodysplastic/Mycloprolifcrative Neoplasms (MDS/MPN)
Chair: Eva llcllstrom-Lindbcrg (Stockholm)
Integration of somatic mutations into classification and Luca Malcovati (Pavia)
prognostic scores in MDS
Discussion
17:40-17:45
Implications of patient genome on clinical decision making Michaela Fontenay (Paris)
in MDS/MPN
Discussion
17:45-18:10
18:10-18:15
Personalized transplantation procedures in myeloid malignancies Matteo Della Porta (Milan)
Discussion
18:15-18:40
Treating anaemia according to patient genome Eva Hellstrom-Lindberg
18:40-18:45
Discussion
18:45-19:15
Round table/general discussion
20.00
Dinner
17:15-17:40
(Stockholm)
Saturday, March 11,2017
08:45-09:45
Meet the Expert sessions
"Choosing Wisely" - Distinction between Clinically Relevant Genomic Information which is
Crucial for Decision Making vs. Academic Interest
MPN - Andreas Hochhaus (Jena)
AML - Robert P. Gale (London)
MDS - Matteo Della Porta (Milan)
CLL - Gianluca Gaidano (Novara)
3
SESSION VII
Personalized Treatment Strategies in Lymphoprolifcrative Disorders
Chair: Gianluca Gaidano (Novara)
09:45-10:10
Therapeutic targeting of biology in CLL: focus on signaling kinase
Stephan Stilgenbauer (Ulm)
and apoptosis modulation
Discussion
10:10-10:15
10:15-10:40
Gianluca Gaidano (Novara)
10:40-10:45
Mutations in CLL and how they
affect therapy choice (focus on NOTCH 1, SF3B1, and TP53)
Discussion
10:45-11:10
11:10-11:15
Genomic stratification for the treatment of lymphomas
Discussion
Laura Pasqualucci (New York)
11:15-11:40
11:40-11:45
Hairy cell leukaemia: targeting mutant BRAF
Discussion
Brunangelo Falini (Perugia)
11:45-12:15
Round lable/general discussion
12:15-12:30
Closing Remarks
MEETING CLOSURE
4
Related documents
Link to this page
Permanent link
Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..
Short link
Use the short link to share your document on Twitter or by text message (SMS)
HTML Code
Copy the following HTML code to share your document on a Website or Blog
QR Code
